Interleukin 8 Released After Acute Myocardial Infarction is Mainly Bound to Erythrocytes

Overview

Journal Heart

Date 1998 Feb 21

PMID 9470879

Citations 10

Authors

R J de Winter

A Manten

Y P de Jong

R Adams

S J van Deventer

K I Lie

Affiliations

Soon will be listed here.

Abstract

Objective: To determine whether rapid clearance of interleukin 8 (IL-8) from plasma through binding to the erythrocyte chemokine receptor may be responsible for failure to detect IL-8 consistently after acute myocardial infarction.

Design: Plasma concentrations of IL-8 were measured at frequent intervals in 43 consecutive patients. In 21 of these, erythrocyte bound IL-8 concentrations were also measured. The influence of infarct size, type of treatment, and the presence of early successful reperfusion on IL-8 release was assessed.

Results: Peak IL-8 concentrations in plasma were raised in 31 of the 43 patients (68%). Median plasma IL-8 concentrations were 16.0 pg/ml (range 2.4 to 225.0 pg/ml) six hours after the onset of chest pain. Twelve hours after the onset of symptoms, plasma IL-8 concentrations had already returned to normal in 27 patients. In contrast, in 18 of 21 patients (86%), erythrocyte bound IL-8 concentrations were raised at between 6 and 30 hours, with a median peak value of 59.8 pg/ml (range 19 to 148 pg/ml). No correlation between peak creatine kinase MB and peak IL-8 (plasma or erythrocyte bound) was observed. There was a significant difference in peak plasma IL-8 concentrations between patients who underwent direct PTCA (19.4 pg/ml) and those who received conservative treatment (9.9 pg/ml; p = 0.0206), but no correlation with the presence of early successful reperfusion.

Conclusions: IL-8 is released in plasma after acute myocardial infarction and subsequently binds to red blood cells, resulting in only a transient rise of plasma IL-8 and a more prolonged increase of erythrocyte bound IL-8.

Citing Articles

Vitamin C-Dependent Uptake of Non-Heme Iron by Enterocytes, Its Impact on Erythropoiesis and Redox Capacity of Human Erythrocytes.

Pan X, Koberle M, Ghashghaeinia M Antioxidants (Basel). 2024; 13(8).

PMID: 39199214 PMC: 11352176. DOI: 10.3390/antiox13080968.

Daily oral administration of probiotics engineered to constantly secrete short-chain fatty acids effectively prevents myocardial injury from subsequent ischaemic heart disease.

Pham Q, Bui T, Sim W, Lim K, Law C, Tan W Cardiovasc Res. 2024; 120(14):1737-1751.

PMID: 38850165 PMC: 11587561. DOI: 10.1093/cvr/cvae128.

Interferon-β decreases LPS-induced neutrophil recruitment to cardiac fibroblasts.

Anfossi R, Vivar R, Ayala P, Gonzalez-Herrera F, Espinoza-Perez C, Osorio J Front Cell Dev Biol. 2023; 11:1122408.

PMID: 37799272 PMC: 10547890. DOI: 10.3389/fcell.2023.1122408.

Human erythrocytes, nuclear factor kappaB (NFκB) and hydrogen sulfide (HS) - from non-genomic to genomic research.

Ghashghaeinia M, Mrowietz U Cell Cycle. 2021; 20(20):2091-2101.

PMID: 34559024 PMC: 8565816. DOI: 10.1080/15384101.2021.1972557.

Colocalization of Erythrocytes and Vascular Calcification in Human Atherosclerosis: A Systematic Histomorphometric Analysis.

Bohm E, Pavlaki M, Chalikias G, Mikroulis D, Georgiadis G, Tziakas D TH Open. 2021; 5(2):e113-e124.

PMID: 33870075 PMC: 8046517. DOI: 10.1055/s-0041-1725042.

References

Entman M, Michael L, Rossen R, Dreyer W, Anderson D, Taylor A . Inflammation in the course of early myocardial ischemia. FASEB J. 1991; 5(11):2529-37. DOI: 10.1096/fasebj.5.11.1868978. View

Johnson K, Aarden L, Choi Y, de Groot E, Creasey A . The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood. 1996; 87(12):5051-60. View

Huber A, Kunkel S, Todd 3rd R, Weiss S . Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science. 1991; 254(5028):99-102. DOI: 10.1126/science.1718038. View

Sturk A, Hack C, Aarden L, Brouwer M, Koster R, Sanders G . Interleukin-6 release and the acute-phase reaction in patients with acute myocardial infarction: a pilot study. J Lab Clin Med. 1992; 119(5):574-9. View

Rot A . Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol Today. 1992; 13(8):291-4. DOI: 10.1016/0167-5699(92)90039-A. View

Ma X, Lefer D, Lefer A, Rothlein R . Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation. 1992; 86(3):937-46. DOI: 10.1161/01.cir.86.3.937. View

Ikeda U, Ohkawa F, Seino Y, Yamamoto K, Hidaka Y, Kasahara T . Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol. 1992; 24(6):579-84. DOI: 10.1016/0022-2828(92)91042-4. View

BRADY A, Williams F, Williams T . Inflammatory injury in myocardial ischaemia. Clin Sci (Lond). 1992; 83(5):511-8. DOI: 10.1042/cs0830511. View

Westlin W, Gimbrone Jr M . Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. Am J Pathol. 1993; 142(1):117-28. PMC: 1886820. View

10.

Tanaka M, Brooks S, Richard V, FitzHarris G, Stoler R, Jennings R . Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation. 1993; 87(2):526-35. DOI: 10.1161/01.cir.87.2.526. View

11.

Zabel M, Hohnloser S, Koster W, Prinz M, Kasper W, Just H . Analysis of creatine kinase, CK-MB, myoglobin, and troponin T time-activity curves for early assessment of coronary artery reperfusion after intravenous thrombolysis. Circulation. 1993; 87(5):1542-50. DOI: 10.1161/01.cir.87.5.1542. View

12.

Siminiak T, Schroder J, Sticherling M, Wysocki H . Interleukin-8 is not involved in the increased chemotactic activity of peripheral blood plasma during acute myocardial infarction. Basic Res Cardiol. 1993; 88(2):150-4. DOI: 10.1007/BF00798263. View

13.

Neote K, Darbonne W, Ogez J, Horuk R, Schall T . Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. J Biol Chem. 1993; 268(17):12247-9. View

14.

Tilg H, Pape D, Trehu E, Shapiro L, Atkins M, Dinarello C . A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy. J Immunol Methods. 1993; 163(2):253-8. DOI: 10.1016/0022-1759(93)90129-u. View

15.

Pietila K, Harmoinen A, Hermens W, Simoons M, Van de Werf F, Verstraete M . Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J. 1993; 14(7):915-9. DOI: 10.1093/eurheartj/14.7.915. View

16.

Tilg H, Shapiro L, Atkins M, Dinarello C, Mier J . Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J Immunol. 1993; 151(6):3299-307. View

17.

Baggiolini M, DEWALD B, Moser B . Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines. Adv Immunol. 1994; 55:97-179. View

18.

Latini R, Bianchi M, CORREALE E, Dinarello C, Fantuzzi G, Fresco C . Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol. 1994; 23(1):1-6. View

19.

Horuk R . The interleukin-8-receptor family: from chemokines to malaria. Immunol Today. 1994; 15(4):169-74. DOI: 10.1016/0167-5699(94)90314-X. View

20.

Neote K, Mak J, Kolakowski Jr L, Schall T . Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood. 1994; 84(1):44-52. View